Eur Rev Med Pharmacol Sci:不同剂量地佐辛对全身麻醉下老年腹部手术患者的镇痛效果及对术后气管拔管应激反应的影响

2018-03-04 李华宇 MedSci原创

地佐辛能有效增强全身麻醉下老年腹部手术患者术后的镇痛效果且呈剂量依赖性。 此外,地佐辛还能显着降低老年患者术后气管拔管的应激反应,降低其全麻腹部手术后不良反应的发生率。

背景与目的

研究不同剂量地佐辛对全身麻醉下老年腹部手术患者的镇痛效果,及探讨地佐辛对术后气管拔管应激反应的影响。

方  法

选取2015年1月至2016年1月在我院接受全身麻醉下行腹部手术及术后镇痛的76例老年患者,选取芬太尼组为对照组(芬太尼10μg/ kg,n = 19) 。随机分为低剂量组(地佐辛0.05 mg / kg,n = 19),中剂量组(地佐辛0.1 mg / kg,n = 19)和高剂量组(地佐辛0.15 mg / kg,n = 19)。每组患者均静脉注射0.1mg / kg的托烷司琼。每组患者在拔出气管导管前及拔管后10 min,详细记录其心率(HR),呼吸频率(RR),平均动脉压(MAP),脉搏氧饱和度(SpO2),此外,观察并评估四组患者术后 4h, 8h, 12h, 24h 及 48 h的视觉模拟量表(VAS)评分、拉姆齐镇静评分、不良反应的发生率、舒适评分(BCS)及镇痛泵按压次数。

结  果

拔管前与拔管后10 min相比,低剂量组,中剂量组和高剂量组三组患者HR,RR,MAP及SPO2差异无统计学意义,但对照组拔管后HR,RR,MAP和SPO2显着增加(p <0.05)。48h内VAS评分低剂量组显着高于对照组,中剂量组和高剂量组(P <0.05)。低剂量组和中剂量组的Ramsay镇静评分明显低于对照组和高剂量组(P <0.05),低剂量组的BCS评分低于中剂量组,高剂量组和对照组(P <0.05)。此外,对照组和低剂量组的患者术后不良反应发生率均高于中剂量组和高剂量组(p <0.05),低剂量组患者的镇痛泵按压次数多于对照组、中剂量组及高剂量组,且低剂量、中剂量组及高剂量按压次数逐渐减少。最后,相关分析结果显示,地佐辛的剂量与Ramsay镇静评分呈正相关,但与患者的VAS评分呈负相关。

结  论

地佐辛能有效增强全身麻醉下老年腹部手术患者术后的镇痛效果且呈剂量依赖性。 此外,地佐辛还能显着降低老年患者术后气管拔管的应激反应,降低其全麻腹部手术后不良反应的发生率。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1653843, encodeId=26ba165384331, content=<a href='/topic/show?id=9e7549289e5' target=_blank style='color:#2F92EE;'>#应激反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49289, encryptionId=9e7549289e5, topicName=应激反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ce824383705, createdName=天堂的云, createdTime=Mon Mar 12 06:09:00 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787444, encodeId=d6a31e8744420, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Aug 16 12:09:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908402, encodeId=d24b1908402c2, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Oct 20 10:09:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788294, encodeId=af321e88294d6, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Jun 10 22:09:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996141, encodeId=dfc419961415e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Jan 26 19:09:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756486, encodeId=0fc11e56486a6, content=<a href='/topic/show?id=3bf48568e5e' target=_blank style='color:#2F92EE;'>#腹部手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85687, encryptionId=3bf48568e5e, topicName=腹部手术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=871937156800, createdName=ms622625817193301, createdTime=Sat Nov 03 06:09:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294027, encodeId=28d629402e27, content=学习了.获益匪浅.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Thu Mar 08 06:13:42 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355271, encodeId=fc7d13552e1cb, content=<a href='/topic/show?id=256a96e9990' target=_blank style='color:#2F92EE;'>#镇痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96799, encryptionId=256a96e9990, topicName=镇痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Mar 06 03:09:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445209, encodeId=470a144520920, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Tue Mar 06 03:09:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468886, encodeId=b093146888654, content=<a href='/topic/show?id=f1565621ecd' target=_blank style='color:#2F92EE;'>#拔管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56217, encryptionId=f1565621ecd, topicName=拔管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=529b6946794, createdName=steven_u4, createdTime=Tue Mar 06 03:09:00 CST 2018, time=2018-03-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1653843, encodeId=26ba165384331, content=<a href='/topic/show?id=9e7549289e5' target=_blank style='color:#2F92EE;'>#应激反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49289, encryptionId=9e7549289e5, topicName=应激反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ce824383705, createdName=天堂的云, createdTime=Mon Mar 12 06:09:00 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787444, encodeId=d6a31e8744420, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Aug 16 12:09:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908402, encodeId=d24b1908402c2, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Oct 20 10:09:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788294, encodeId=af321e88294d6, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Jun 10 22:09:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996141, encodeId=dfc419961415e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Jan 26 19:09:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756486, encodeId=0fc11e56486a6, content=<a href='/topic/show?id=3bf48568e5e' target=_blank style='color:#2F92EE;'>#腹部手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85687, encryptionId=3bf48568e5e, topicName=腹部手术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=871937156800, createdName=ms622625817193301, createdTime=Sat Nov 03 06:09:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294027, encodeId=28d629402e27, content=学习了.获益匪浅.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Thu Mar 08 06:13:42 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355271, encodeId=fc7d13552e1cb, content=<a href='/topic/show?id=256a96e9990' target=_blank style='color:#2F92EE;'>#镇痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96799, encryptionId=256a96e9990, topicName=镇痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Mar 06 03:09:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445209, encodeId=470a144520920, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Tue Mar 06 03:09:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468886, encodeId=b093146888654, content=<a href='/topic/show?id=f1565621ecd' target=_blank style='color:#2F92EE;'>#拔管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56217, encryptionId=f1565621ecd, topicName=拔管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=529b6946794, createdName=steven_u4, createdTime=Tue Mar 06 03:09:00 CST 2018, time=2018-03-06, status=1, ipAttribution=)]
    2018-08-16 jj000001
  3. [GetPortalCommentsPageByObjectIdResponse(id=1653843, encodeId=26ba165384331, content=<a href='/topic/show?id=9e7549289e5' target=_blank style='color:#2F92EE;'>#应激反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49289, encryptionId=9e7549289e5, topicName=应激反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ce824383705, createdName=天堂的云, createdTime=Mon Mar 12 06:09:00 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787444, encodeId=d6a31e8744420, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Aug 16 12:09:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908402, encodeId=d24b1908402c2, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Oct 20 10:09:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788294, encodeId=af321e88294d6, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Jun 10 22:09:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996141, encodeId=dfc419961415e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Jan 26 19:09:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756486, encodeId=0fc11e56486a6, content=<a href='/topic/show?id=3bf48568e5e' target=_blank style='color:#2F92EE;'>#腹部手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85687, encryptionId=3bf48568e5e, topicName=腹部手术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=871937156800, createdName=ms622625817193301, createdTime=Sat Nov 03 06:09:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294027, encodeId=28d629402e27, content=学习了.获益匪浅.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Thu Mar 08 06:13:42 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355271, encodeId=fc7d13552e1cb, content=<a href='/topic/show?id=256a96e9990' target=_blank style='color:#2F92EE;'>#镇痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96799, encryptionId=256a96e9990, topicName=镇痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Mar 06 03:09:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445209, encodeId=470a144520920, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Tue Mar 06 03:09:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468886, encodeId=b093146888654, content=<a href='/topic/show?id=f1565621ecd' target=_blank style='color:#2F92EE;'>#拔管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56217, encryptionId=f1565621ecd, topicName=拔管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=529b6946794, createdName=steven_u4, createdTime=Tue Mar 06 03:09:00 CST 2018, time=2018-03-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1653843, encodeId=26ba165384331, content=<a href='/topic/show?id=9e7549289e5' target=_blank style='color:#2F92EE;'>#应激反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49289, encryptionId=9e7549289e5, topicName=应激反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ce824383705, createdName=天堂的云, createdTime=Mon Mar 12 06:09:00 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787444, encodeId=d6a31e8744420, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Aug 16 12:09:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908402, encodeId=d24b1908402c2, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Oct 20 10:09:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788294, encodeId=af321e88294d6, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Jun 10 22:09:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996141, encodeId=dfc419961415e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Jan 26 19:09:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756486, encodeId=0fc11e56486a6, content=<a href='/topic/show?id=3bf48568e5e' target=_blank style='color:#2F92EE;'>#腹部手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85687, encryptionId=3bf48568e5e, topicName=腹部手术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=871937156800, createdName=ms622625817193301, createdTime=Sat Nov 03 06:09:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294027, encodeId=28d629402e27, content=学习了.获益匪浅.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Thu Mar 08 06:13:42 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355271, encodeId=fc7d13552e1cb, content=<a href='/topic/show?id=256a96e9990' target=_blank style='color:#2F92EE;'>#镇痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96799, encryptionId=256a96e9990, topicName=镇痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Mar 06 03:09:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445209, encodeId=470a144520920, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Tue Mar 06 03:09:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468886, encodeId=b093146888654, content=<a href='/topic/show?id=f1565621ecd' target=_blank style='color:#2F92EE;'>#拔管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56217, encryptionId=f1565621ecd, topicName=拔管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=529b6946794, createdName=steven_u4, createdTime=Tue Mar 06 03:09:00 CST 2018, time=2018-03-06, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1653843, encodeId=26ba165384331, content=<a href='/topic/show?id=9e7549289e5' target=_blank style='color:#2F92EE;'>#应激反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49289, encryptionId=9e7549289e5, topicName=应激反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ce824383705, createdName=天堂的云, createdTime=Mon Mar 12 06:09:00 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787444, encodeId=d6a31e8744420, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Aug 16 12:09:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908402, encodeId=d24b1908402c2, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Oct 20 10:09:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788294, encodeId=af321e88294d6, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Jun 10 22:09:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996141, encodeId=dfc419961415e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Jan 26 19:09:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756486, encodeId=0fc11e56486a6, content=<a href='/topic/show?id=3bf48568e5e' target=_blank style='color:#2F92EE;'>#腹部手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85687, encryptionId=3bf48568e5e, topicName=腹部手术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=871937156800, createdName=ms622625817193301, createdTime=Sat Nov 03 06:09:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294027, encodeId=28d629402e27, content=学习了.获益匪浅.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Thu Mar 08 06:13:42 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355271, encodeId=fc7d13552e1cb, content=<a href='/topic/show?id=256a96e9990' target=_blank style='color:#2F92EE;'>#镇痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96799, encryptionId=256a96e9990, topicName=镇痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Mar 06 03:09:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445209, encodeId=470a144520920, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Tue Mar 06 03:09:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468886, encodeId=b093146888654, content=<a href='/topic/show?id=f1565621ecd' target=_blank style='color:#2F92EE;'>#拔管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56217, encryptionId=f1565621ecd, topicName=拔管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=529b6946794, createdName=steven_u4, createdTime=Tue Mar 06 03:09:00 CST 2018, time=2018-03-06, status=1, ipAttribution=)]
    2019-01-26 yb6560
  6. [GetPortalCommentsPageByObjectIdResponse(id=1653843, encodeId=26ba165384331, content=<a href='/topic/show?id=9e7549289e5' target=_blank style='color:#2F92EE;'>#应激反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49289, encryptionId=9e7549289e5, topicName=应激反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ce824383705, createdName=天堂的云, createdTime=Mon Mar 12 06:09:00 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787444, encodeId=d6a31e8744420, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Aug 16 12:09:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908402, encodeId=d24b1908402c2, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Oct 20 10:09:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788294, encodeId=af321e88294d6, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Jun 10 22:09:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996141, encodeId=dfc419961415e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Jan 26 19:09:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756486, encodeId=0fc11e56486a6, content=<a href='/topic/show?id=3bf48568e5e' target=_blank style='color:#2F92EE;'>#腹部手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85687, encryptionId=3bf48568e5e, topicName=腹部手术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=871937156800, createdName=ms622625817193301, createdTime=Sat Nov 03 06:09:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294027, encodeId=28d629402e27, content=学习了.获益匪浅.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Thu Mar 08 06:13:42 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355271, encodeId=fc7d13552e1cb, content=<a href='/topic/show?id=256a96e9990' target=_blank style='color:#2F92EE;'>#镇痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96799, encryptionId=256a96e9990, topicName=镇痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Mar 06 03:09:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445209, encodeId=470a144520920, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Tue Mar 06 03:09:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468886, encodeId=b093146888654, content=<a href='/topic/show?id=f1565621ecd' target=_blank style='color:#2F92EE;'>#拔管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56217, encryptionId=f1565621ecd, topicName=拔管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=529b6946794, createdName=steven_u4, createdTime=Tue Mar 06 03:09:00 CST 2018, time=2018-03-06, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1653843, encodeId=26ba165384331, content=<a href='/topic/show?id=9e7549289e5' target=_blank style='color:#2F92EE;'>#应激反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49289, encryptionId=9e7549289e5, topicName=应激反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ce824383705, createdName=天堂的云, createdTime=Mon Mar 12 06:09:00 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787444, encodeId=d6a31e8744420, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Aug 16 12:09:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908402, encodeId=d24b1908402c2, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Oct 20 10:09:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788294, encodeId=af321e88294d6, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Jun 10 22:09:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996141, encodeId=dfc419961415e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Jan 26 19:09:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756486, encodeId=0fc11e56486a6, content=<a href='/topic/show?id=3bf48568e5e' target=_blank style='color:#2F92EE;'>#腹部手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85687, encryptionId=3bf48568e5e, topicName=腹部手术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=871937156800, createdName=ms622625817193301, createdTime=Sat Nov 03 06:09:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294027, encodeId=28d629402e27, content=学习了.获益匪浅.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Thu Mar 08 06:13:42 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355271, encodeId=fc7d13552e1cb, content=<a href='/topic/show?id=256a96e9990' target=_blank style='color:#2F92EE;'>#镇痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96799, encryptionId=256a96e9990, topicName=镇痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Mar 06 03:09:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445209, encodeId=470a144520920, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Tue Mar 06 03:09:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468886, encodeId=b093146888654, content=<a href='/topic/show?id=f1565621ecd' target=_blank style='color:#2F92EE;'>#拔管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56217, encryptionId=f1565621ecd, topicName=拔管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=529b6946794, createdName=steven_u4, createdTime=Tue Mar 06 03:09:00 CST 2018, time=2018-03-06, status=1, ipAttribution=)]
    2018-03-08 13718711b3m

    学习了.获益匪浅.感谢分享

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1653843, encodeId=26ba165384331, content=<a href='/topic/show?id=9e7549289e5' target=_blank style='color:#2F92EE;'>#应激反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49289, encryptionId=9e7549289e5, topicName=应激反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ce824383705, createdName=天堂的云, createdTime=Mon Mar 12 06:09:00 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787444, encodeId=d6a31e8744420, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Aug 16 12:09:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908402, encodeId=d24b1908402c2, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Oct 20 10:09:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788294, encodeId=af321e88294d6, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Jun 10 22:09:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996141, encodeId=dfc419961415e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Jan 26 19:09:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756486, encodeId=0fc11e56486a6, content=<a href='/topic/show?id=3bf48568e5e' target=_blank style='color:#2F92EE;'>#腹部手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85687, encryptionId=3bf48568e5e, topicName=腹部手术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=871937156800, createdName=ms622625817193301, createdTime=Sat Nov 03 06:09:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294027, encodeId=28d629402e27, content=学习了.获益匪浅.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Thu Mar 08 06:13:42 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355271, encodeId=fc7d13552e1cb, content=<a href='/topic/show?id=256a96e9990' target=_blank style='color:#2F92EE;'>#镇痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96799, encryptionId=256a96e9990, topicName=镇痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Mar 06 03:09:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445209, encodeId=470a144520920, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Tue Mar 06 03:09:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468886, encodeId=b093146888654, content=<a href='/topic/show?id=f1565621ecd' target=_blank style='color:#2F92EE;'>#拔管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56217, encryptionId=f1565621ecd, topicName=拔管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=529b6946794, createdName=steven_u4, createdTime=Tue Mar 06 03:09:00 CST 2018, time=2018-03-06, status=1, ipAttribution=)]
    2018-03-06 zhaojie88
  9. [GetPortalCommentsPageByObjectIdResponse(id=1653843, encodeId=26ba165384331, content=<a href='/topic/show?id=9e7549289e5' target=_blank style='color:#2F92EE;'>#应激反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49289, encryptionId=9e7549289e5, topicName=应激反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ce824383705, createdName=天堂的云, createdTime=Mon Mar 12 06:09:00 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787444, encodeId=d6a31e8744420, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Aug 16 12:09:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908402, encodeId=d24b1908402c2, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Oct 20 10:09:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788294, encodeId=af321e88294d6, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Jun 10 22:09:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996141, encodeId=dfc419961415e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Jan 26 19:09:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756486, encodeId=0fc11e56486a6, content=<a href='/topic/show?id=3bf48568e5e' target=_blank style='color:#2F92EE;'>#腹部手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85687, encryptionId=3bf48568e5e, topicName=腹部手术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=871937156800, createdName=ms622625817193301, createdTime=Sat Nov 03 06:09:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294027, encodeId=28d629402e27, content=学习了.获益匪浅.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Thu Mar 08 06:13:42 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355271, encodeId=fc7d13552e1cb, content=<a href='/topic/show?id=256a96e9990' target=_blank style='color:#2F92EE;'>#镇痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96799, encryptionId=256a96e9990, topicName=镇痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Mar 06 03:09:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445209, encodeId=470a144520920, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Tue Mar 06 03:09:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468886, encodeId=b093146888654, content=<a href='/topic/show?id=f1565621ecd' target=_blank style='color:#2F92EE;'>#拔管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56217, encryptionId=f1565621ecd, topicName=拔管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=529b6946794, createdName=steven_u4, createdTime=Tue Mar 06 03:09:00 CST 2018, time=2018-03-06, status=1, ipAttribution=)]
  10. [GetPortalCommentsPageByObjectIdResponse(id=1653843, encodeId=26ba165384331, content=<a href='/topic/show?id=9e7549289e5' target=_blank style='color:#2F92EE;'>#应激反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49289, encryptionId=9e7549289e5, topicName=应激反应)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ce824383705, createdName=天堂的云, createdTime=Mon Mar 12 06:09:00 CST 2018, time=2018-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1787444, encodeId=d6a31e8744420, content=<a href='/topic/show?id=fa03141591e' target=_blank style='color:#2F92EE;'>#Pharm#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14159, encryptionId=fa03141591e, topicName=Pharm)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8942242, createdName=jj000001, createdTime=Thu Aug 16 12:09:00 CST 2018, time=2018-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1908402, encodeId=d24b1908402c2, content=<a href='/topic/show?id=a8d0141605e' target=_blank style='color:#2F92EE;'>#pharma#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14160, encryptionId=a8d0141605e, topicName=pharma)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f634250, createdName=chentianping, createdTime=Sat Oct 20 10:09:00 CST 2018, time=2018-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1788294, encodeId=af321e88294d6, content=<a href='/topic/show?id=38e014162e2' target=_blank style='color:#2F92EE;'>#Pharmacol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14162, encryptionId=38e014162e2, topicName=Pharmacol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=930e243, createdName=dingxiaobo, createdTime=Sun Jun 10 22:09:00 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996141, encodeId=dfc419961415e, content=<a href='/topic/show?id=ed881120ec8' target=_blank style='color:#2F92EE;'>#MAC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11207, encryptionId=ed881120ec8, topicName=MAC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sat Jan 26 19:09:00 CST 2019, time=2019-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1756486, encodeId=0fc11e56486a6, content=<a href='/topic/show?id=3bf48568e5e' target=_blank style='color:#2F92EE;'>#腹部手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85687, encryptionId=3bf48568e5e, topicName=腹部手术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=871937156800, createdName=ms622625817193301, createdTime=Sat Nov 03 06:09:00 CST 2018, time=2018-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=294027, encodeId=28d629402e27, content=学习了.获益匪浅.感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Thu Mar 08 06:13:42 CST 2018, time=2018-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355271, encodeId=fc7d13552e1cb, content=<a href='/topic/show?id=256a96e9990' target=_blank style='color:#2F92EE;'>#镇痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96799, encryptionId=256a96e9990, topicName=镇痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Mar 06 03:09:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1445209, encodeId=470a144520920, content=<a href='/topic/show?id=61e74928629' target=_blank style='color:#2F92EE;'>#应激#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49286, encryptionId=61e74928629, topicName=应激)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79df5138909, createdName=ms1260584454294838, createdTime=Tue Mar 06 03:09:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468886, encodeId=b093146888654, content=<a href='/topic/show?id=f1565621ecd' target=_blank style='color:#2F92EE;'>#拔管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56217, encryptionId=f1565621ecd, topicName=拔管)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=529b6946794, createdName=steven_u4, createdTime=Tue Mar 06 03:09:00 CST 2018, time=2018-03-06, status=1, ipAttribution=)]
    2018-03-06 steven_u4

相关资讯

PLoS One:ICU镇静镇痛药物的年龄相关剂量关系

重症监护室(ICU)中的镇静和镇痛常基于麻醉方式,而不考虑患者相关因素。ICU麻醉期间镇静剂和镇痛药物的连续输注与推注或短期输注相比,镇静药和镇痛药的药理学特性发生了变化。

Anesthesiology :硬膜外药物输注速率对分娩镇痛效果的影响:随机临床试验

研究表明,硬膜外分娩镇痛时局部麻醉药间断使用比持续输注有更好的镇痛效果,且硬膜外高速输注增加导管处的输送压力,并可改善硬膜外腔中的药物分布。本研究假设高速硬膜外输注可改善硬膜外分娩镇痛效果及药物使用量。

美国妇产科医师学会“2017 产科镇痛和麻醉实践指南”解读

产科麻醉及分娩镇痛是当代产科热点话题,国内外均有大量研究及临床实践,如何规范产科麻醉及分娩镇痛值得每一位产科医护人员思考。2017 年4 月,美国妇产科医师协会颁布了“2017 产科镇痛和麻醉实践指南”,该指南更新了该协会早在2002 年、2004年、2006 年及2007 年颁布的相关指南及专家共识,回顾了分娩期间常用的镇痛和麻醉药物,但是没有提及非药物镇痛,如按摩、水疗、针灸、放松、催眠等辅助

Anesth Analg:持续性罗哌卡因切口局部浸润与鞘内注射吗啡在剖宫产后镇痛效果中的比较:前瞻性、随机对照、双盲试验

剖宫产后,术后疼痛管理可以促进早期康复,有助于预防产后抑郁症和慢性疼痛。目前的前瞻性、随机对照、双盲研究评估了剖宫产分娩后鞘内镇痛和连续罗哌卡因伤口浸润的持续时间和作用。主要结局是镇痛持续时间,其定义为首次增加使用吗啡的时间。次要结局是术后吗啡的累积用量,不需使用吗啡的患者数量,不良反应的发生率和首次下床活动的时间。

Anesthesiology:Src激酶抑制剂减轻吗啡耐受而不影响增加效应或精神运动刺激

延长的阿片类药物给药时间会导致以镇痛效力降低为特征的耐受性。阿片类药物产生的快感效应,也是其滥用的原因之一。多功能蛋白β-抑制蛋白2可调节吗啡的快感效应,也参与耐受性。这些行为可能通过减少内吞反应为μ阿片受体上调。β-抑制蛋白2还募集了μ受体的激酶。我们探讨了Src激酶对C57BL / 6小鼠的吗啡镇痛耐受性、运动刺激和强化效应中的作用。

七成疼痛患者未规范化镇痛治疗,阿片类药物用不用?

2017年中国癌症统计年报数据显示,中国癌症患者的数量不断攀升,癌症新发人数增加到459万,占世界的1/4。疼痛是肿瘤患者最常见的伴随性疾病,60%在接受抗肿瘤治疗的患者会出现疼痛,然而70%的疼痛患者未接受规范化的镇痛治疗。“作为目前已发现的镇痛作用最强、止痛疗效最确切的药物,阿片类药物是治疗癌痛的首选,这是世界范围内的共识,得到了美国国立综合癌症网络(NCCN)、欧洲临床肿瘤学会(ESMO)、